|Primary analysis complete
|Study Start Date:
|Study Made Public:
A multicenter, double-blind, randomized, placebo-controlled Phase II proof-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Merck adenovirus serotype 5 HIV-1 gag/pol/nef vaccine (MRKAd5 HIV-1 gag/pol/nef) in adults at high risk of HIV-1 infection
HVTN 502 (STEP study/Merck V520-023) is a Phase II clinical trial to evaluate the safety and immunogenicity of MRKAd5 HIV-1 gag/pol/nef (Ad5).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.